Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global ardiopulmonary Stress Testing Systems market in this environment.
In terms of revenue, this research report indicated that the global ardiopulmonary Stress Testing Systems market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of ardiopulmonary Stress Testing Systems industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The BD aims at producing XX K Units ardiopulmonary Stress Testing Systems in 2020, with XX % production to take place in global market, GE Healthcare accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of ardiopulmonary Stress Testing Systems Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in ardiopulmonary Stress Testing Systems Market
BD
GE Healthcare
Philips Healthcare
Spacelabs Healthcare
Cardinal Health
Fukuda Denshi
MGC Diagnostic
Mortara Instrument
Nihon Kohden
Schiller
SunTech Medical
Welch Allyn
...
Major Type of ardiopulmonary Stress Testing Systems Covered in Prudent Markets report:
CPET
Stress ECG
SPECT
Stress Blood Pressure Monitor
Pulse Oximeter
Application Segments Covered in Prudent Markets Market
Physical Examination Center
Hospital
Clinic
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global ardiopulmonary Stress Testing Systems Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 CPET -Product Introduction and Major Manufacturers
1.1.2 Stress ECG -Product Introduction and Major Manufacturers
1.1.3 SPECT -Product Introduction and Major Manufacturers
1.1.4 Stress Blood Pressure Monitor -Product Introduction and Major Manufacturers
1.1.5 Pulse Oximeter -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global ardiopulmonary Stress Testing Systems Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China ardiopulmonary Stress Testing Systems Market
3.1.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU ardiopulmonary Stress Testing Systems Market
3.2.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA ardiopulmonary Stress Testing Systems Market
3.3.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan ardiopulmonary Stress Testing Systems Market
3.4.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India ardiopulmonary Stress Testing Systems Market
3.5.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia ardiopulmonary Stress Testing Systems Market
3.6.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America ardiopulmonary Stress Testing Systems Market
3.7.1 Top Companies leading ardiopulmonary Stress Testing Systems Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America ardiopulmonary Stress Testing Systems Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 ardiopulmonary Stress Testing Systems Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on ardiopulmonary Stress Testing Systems Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global ardiopulmonary Stress Testing Systems Sales and Growth Rate (2021-2027)
5.2 Global ardiopulmonary Stress Testing Systems Sales Value and Growth Rate (2021-2027)
6 ardiopulmonary Stress Testing Systems Competitive Analysis
6.1 BD
6.1.1 BD Company Profiles
6.1.2 BD Product Introduction
6.1.3 BD ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 GE Healthcare
6.2.1 GE Healthcare Company Profiles
6.2.2 GE Healthcare Product Introduction
6.2.3 GE Healthcare ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Philips Healthcare
6.3.1 Philips Healthcare Company Profiles
6.3.2 Philips Healthcare Product Introduction
6.3.3 Philips Healthcare ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Spacelabs Healthcare
6.4.1 Spacelabs Healthcare Company Profiles
6.4.2 Spacelabs Healthcare Product Introduction
6.4.3 Spacelabs Healthcare ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Cardinal Health
6.5.1 Cardinal Health Company Profiles
6.5.2 Cardinal Health Product Introduction
6.5.3 Cardinal Health ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Fukuda Denshi
6.6.1 Fukuda Denshi Company Profiles
6.6.2 Fukuda Denshi Product Introduction
6.6.3 Fukuda Denshi ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 MGC Diagnostic
6.7.1 MGC Diagnostic Company Profiles
6.7.2 MGC Diagnostic Product Introduction
6.7.3 MGC Diagnostic ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Mortara Instrument
6.8.1 Mortara Instrument Company Profiles
6.8.2 Mortara Instrument Product Introduction
6.8.3 Mortara Instrument ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Nihon Kohden
6.9.1 Nihon Kohden Company Profiles
6.9.2 Nihon Kohden Product Introduction
6.9.3 Nihon Kohden ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Schiller
6.10.1 Schiller Company Profiles
6.10.2 Schiller Product Introduction
6.10.3 Schiller ardiopulmonary Stress Testing Systems Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 SunTech Medical
6.12 Welch Allyn
7 Conclusion